Affordable Access

Publisher Website

Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study.

  • Hsu, Chung-Yuan1
  • Lin, Ming-Shyan2
  • Su, Yu-Jih1
  • Cheng, Tien-Tsai1
  • Lin, Yu-Sheng3, 4
  • Chen, Ying-Chou1
  • Chiu, Wen-Chan1
  • Chen, Tien-Hsing5
  • 1 Division of Rheumatology, Allergy, and Immunology, Department of Internal Medicine Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung.
  • 2 Division of Cardiology, Chang-Gung Memorial Hospital, Yunlin.
  • 3 Division of Cardiology, Chang Gung Memorial Hospital, Chiayi.
  • 4 School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan County.
  • 5 Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Keelung, Taiwan. , (Taiwan)
Published Article
Rheumatology (Oxford, England)
Publication Date
Apr 01, 2017
DOI: 10.1093/rheumatology/kew457
PMID: 28039419


Immunosuppressive therapy is necessary to alter the natural course of SLE. However, immunosuppressant-related cancer risk is a major concern. The aim of this study was to determine whether immunosuppressant use is associated with cancer risk in SLE. We designed a retrospective nested case-control study within an SLE population based on the National Health Insurance Research Database in Taiwan. We screened 14 842 patients with SLE from 2001 to 2013 and compared patients with SLE complicated by later cancer with patients with SLE but without cancer. The cumulative dose of immunosuppressants was calculated from the SLE diagnosis date to the occurrence of cancer. The immunosuppressants of interest were AZA, CYC, MTX, HCQ and systemic glucocorticoids. Adjusted odds ratios (ORs) for cancer were calculated in conditional Cox regression models after propensity score matching. The top five types of cancers were breast (16.9%), haematological (11.7%), colorectal (11.0%), lung (10.6%) and hepatobiliary (10.4%) cancers. After matching, this study included 330 cancer patients and 1320 matched cancer-free patients. The adjusted analyses showed an association of a higher cumulative CYC dose (OR = 1.09, 95% CI: 1.04, 1.13) and lower HCQ dose (OR = 0.93, 95% CI: 0.90, 0.97) with cancer risk in comparison with the controls. Diverse cancer risks are associated with different immunosuppressants in patients with SLE. CYC increases the risk of cancer, and HCQ decreases this risk in SLE patients, both in a dose-dependent manner. © The Author 2016. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: [email protected]

Report this publication


Seen <100 times